 from investors including the chip giant Nvidia. Jakob Uszkoreit, one of a team of former Google scientists who developed the AI breakthrough in 2017, is raising the funds to develop 'biological software' that could lead to new treatments. His low-profile company, Inceptive, is one of a number of start-ups hoping to use generative AI to invent new types of drugs. The company designs new types of molecules and then works with major pharmaceutical companies to test them. Nvidia's venture capital arm, the Silicon Valley investor Andreessen Horowitz, and Obvious Ventures, a prolific San Francisco venture capital firm, are among those investing, according to the Financial Times, which revealed the fundraising. Mr Uszkoreit was one of eight scientists, mostly Google employees, who co-authored a seminal scientific paper that unveiled a computing model called a transformer, which has powered the rise of chatbots such as ChatGPT and image and video generation tools. The technology was also used by the Google-owned AI lab Deepmind, which used it to develop a protein-folding program that promises to rapidly improve medical research.){kind=link}
Start-up raises £80m from investors amid plans to use generative AI to invent new drugs
One of the inventors of the technology behind ChatGPT plans to use artificial intelligence to discover new types of medicine after raising $100m (£80m) from investors including the chip giant Nvidia.
Jakob Uszkoreit, one of a team of former Google scientists who developed the AI breakthrough in 2017, is raising the funds to develop “biological software” that could lead to new treatments.
His low-profile company, Inceptive, is one of a number of start-ups hoping to use generative AI to invent new types of drugs. The company designs new types of molecules and then works with major pharmaceutical companies to test them.
Nvidia’s venture capital arm, the Silicon Valley investor Andreessen Horowitz, and Obvious Ventures, a prolific San Francisco venture capital firm, are among those investing, according to the Financial Times, which revealed the fundraising.